Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study

Elliot Smith, Gillian Booth, Wing Chan, Ning Liu, Mithunan Ravindran, Matthew Cheung, Kelvin Chan, Abi Vijenthira, Peter Gozdyra, Ethan Lin, Lee Mozessohn

Blood (2025) 146 (Supplement 1): 8057.

https://doi.org/10.1182/blood-2025-8057

Published: 2025

Journal Articles

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Blood (2025) 146 (Supplement 1): 3862.

https://doi.org/10.1182/blood-2025-3862

Published: 2025

Journal Articles

Test characteristics of end-of-treatment PET scans in diffuse large b-cell lymphoma in a population-level cohort

Samantha Hershenfeld, Daniel McCormack, Ning Liu, Matthew Cheung

Blood (2025) 146 (Supplement 1): 8027.

https://doi.org/10.1182/blood-2025-8027

Published: 2025

Journal Articles

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Blood (2025) 146 (Supplement 1): 964.

https://doi.org/10.1182/blood-2025-964

Published: 2025

Journal Articles

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Blood (2022) 140 (Supplement 1): 9259–9260.

https://doi.org/10.1182/blood-2022-169623

Published: 2022

Journal Articles

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies

Ying Ling, Kelvin Chan, Aditi Patrikar, Ning Liu, Aisha Lofters, Colleen Fox, Simron Singh, Matthew Cheung

Blood (2021) 138 (Supplement 1): 4011.

https://doi.org/10.1182/blood-2021-154227

Published: 2021

Journal Articles

The Impact of Marginalization on Diffuse Large B-Cell Lymphoma Overall Survival: A Retrospective Cohort Study

Sumedha Arya, Lee Mozessohn, Inna Gong, Neil Faught, Ning Liu, Simron Singh, Kelvin Chan, Matthew Cheung

Blood (2021) 138 (Supplement 1): 341.

https://doi.org/10.1182/blood-2021-146642

Published: 2021

Journal Articles

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Eugene Brailovski, Qing Li, Ning Liu, Brian Leber, Dina Khalaf, Mitchell Sabloff, Grace Christou, Karen Yee, Lisa Chodirker, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Ying Liu, Craig C. Earle, Matthew Cheung, Nicole Mittman, Rena J. Buckstein, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2021-149855

Published: 2021

Journal Articles

Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study

Inna Gong, Matthew Cheung, Kelvin Chan, Sumedha Arya, Neil Faught, Ning Liu, Oreofe O. Odejide, Gregory A. Abel, Michael Raphael, Anca Prica, Christopher Booth, Thomas M. Kuczmarski, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2021-149469

Published: 2021

Journal Articles

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis

Inna Gong, Abi Vijenthira, Stephen Betschel, Lisa K. Hicks, Matthew Cheung

Blood (2021) 138 (Supplement 1): 4113.

https://doi.org/10.1182/blood-2021-149652

Published: 2021

Journal Articles

Shared and Distinct Genetic Features in Human and Canine B-Cell Lymphomas

Tiana Hillman, Matthew Cheung, Bruno M. Grande, Kevin R Bushell, Sarah E. Arthur, Miguel Alcaide, Nicole Thomas, Kostiantyn Dreval, Jovanveer Shoker, Krishanna Campbell, Stephanie Wong, Ryan D Morin, Krysta M. Coyle

Blood (2021) 138 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2021-153928

Published: 2021

Journal Articles

Outcomes of Patients with Indolent Lymphoma Treated with Bendamustine Plus Rituximab Compared to Rituximab Plus CVP or CHOP Chemoimmunotherapy in Ontario

Adam Suleman, Suriya Aktar, Ning Liu, Kelvin Chan, Matthew Cheung, Anca Prica

Blood (2021) 138 (Supplement 1): 3546.

https://doi.org/10.1182/blood-2021-148982

Published: 2021

Journal Articles

Are Novel Therapies Worth the Cost for Young Patients?: A Cost-Effectiveness Analysis of Frontline Therapies with or without Radiation for Early-Stage Unfavourable Hodgkin Lymphoma

Abi Vijenthira, David C. Hodgson, Matthew Cheung, Michael Crump, Anca Prica

Blood (2021) 138 (Supplement 1): 662.

https://doi.org/10.1182/blood-2021-151701

Published: 2021

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Yi Ying Regina Li, MD, Soo Jin Seung, Stephanie Y Cheng, Matthew Cheung, MDMSc, Nicole Mittman, PhD MSc

Blood (2019) 134 (Supplement_1): 4745.

https://doi.org/10.1182/blood-2019-131407

Published: 2019

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study

Aniket Bankar, MBBS, MD DM, Haoyu Zhao, Javaid Iqbal, Ruth Coxford, Matthew Cheung, MDMSc, Lee Mozessohn, MD, Craig C. Earle, MD, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4169.

https://doi.org/10.1182/blood-2019-125183

Published: 2019

Journal Articles

Statin and COX-2 Inhibitor Exposure Is Associated with Improved Survival in 4913 Newly Diagnosed DLBCL Patients: A Large Population Based Study

Liam Smyth, MDFRCPath, Danielle N. Blunt, BMBS, Evgenia Gatov, Chenthila Nagamuthu, MPH, Ruth Croxford, MSc, Lee Mozessohn, MD, Matthew Cheung, MDMSc

Blood (2019) 134 (Supplement_1): 3476.

https://doi.org/10.1182/blood-2019-127156

Published: 2019

Journal Articles

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Lee Mozessohn, MD, Matthew Cheung, MD MS, FRCP, Nicole Mittmann, PhD, Craig C. Earle, MD, Ning Liu, Rena Buckstein, MD FRCPC

Blood (2018) 132 (Supplement 1): 834.

https://doi.org/10.1182/blood-2018-99-110223

Published: 2018

Journal Articles

Appropriateness of B12 Administration in a Real-World Population

William K Silverstein, MD, Yulia Lin, MD FRCPC, Christoffer Dharma, MSc, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2018-99-110264

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Test characteristics of end-of-treatment PET scans in diffuse large b-cell lymphoma in a population-level cohort

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies

The Impact of Marginalization on Diffuse Large B-Cell Lymphoma Overall Survival: A Retrospective Cohort Study

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis

Shared and Distinct Genetic Features in Human and Canine B-Cell Lymphomas

Outcomes of Patients with Indolent Lymphoma Treated with Bendamustine Plus Rituximab Compared to Rituximab Plus CVP or CHOP Chemoimmunotherapy in Ontario

Are Novel Therapies Worth the Cost for Young Patients?: A Cost-Effectiveness Analysis of Frontline Therapies with or without Radiation for Early-Stage Unfavourable Hodgkin Lymphoma

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study

Statin and COX-2 Inhibitor Exposure Is Associated with Improved Survival in 4913 Newly Diagnosed DLBCL Patients: A Large Population Based Study

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Appropriateness of B12 Administration in a Real-World Population

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only